Statement on HL161 Licensing Agreement Termination Notification with Harbour BioMed
Statement on HL161 Licensing Agreement Termination Notification with Harbour BioMed
HanAll Biopharma Announces Orphan Drug Designation for Batoclimab in Japan for Active Thyroid Eye Disease
HanAll Biopharma Announces Orphan Drug Designation for Batoclimab in Japan for Active Thyroid Eye Di..
HanAll Biopharma, Daewoong Pharmaceutical and NurrOn Pharmaceuticals Announce Successful Completion of a First-in-Human Study for Potential Disease-Modifying Therapy for Parkinson's Disease
HanAll Biopharma, Daewoong Pharmaceutical and NurrOn Pharmaceuticals Announce Successful Completion ..
HanAll Biopharma Reports Q3 2024 Financial Results and Provides Business
HanAll Biopharma Reports Q3 2024 Financial Results and Provides Business
HanAll Biopharma Reports Q2 2024 Financial Results and Provides Business
HanAll Biopharma Reports Q2 2024 Financial Results and Provides Business
HanAll Biopharma Appoints Christopher W Slavinsky as Chief Business Development and Legal Officer
HanAll Biopharma Appoints Christopher W Slavinsky as Chief Business Development and Legal Officer